Nature Reviews:一文读懂微生物组疗法(综述)
创作:mildbreeze 审核:mildbreeze 02月01日
  • 粪菌移植(FMT)可提供定植抵抗、产生有益代谢物、恢复菌群与粘膜免疫的互作,被研究用于治疗菌群相关疾病(CDI、GVHD、IBD等有较好或一定的临床疗效),供体菌群组成及菌株植入情况可能影响其效果;
  • FMT是权宜疗法,很多共生菌的健康作用已被阐释,如调节免疫和代谢、抑制病菌,这些新知可促成更精准的菌群导向性疗法:食物和益生元、组成明确的共生微生物群落、工程菌、菌群衍生蛋白和代谢物;
  • 这些疗法在科研、商业化和监管方面各有优势和挑战(如安全性、知识产权、质控、产品稳定性等)。
#一张图读懂系列文献#
主编推荐语
mildbreeze
健康的肠道菌群可促进宿主健康。随着人们对肠道菌群及其在健康和疾病中的作用的了解不断深入,靶向菌群的治疗方法应运而生。Nature Reviews Microbiology最新发表的综述文章,以目前研究最多的粪菌移植为切入点展开讨论,并介绍了已知的主要菌门中特定微生物的健康功能,探讨了多种基于菌群的疗法的研究现状、优势和挑战,推荐专业人士参考。
关键字
延伸阅读本研究的原文信息和链接出处,以及相关解读和评论文章。欢迎读者朋友们推荐!

Microbiome-based therapeutics

基于微生物组的疗法

10.1038/s41579-021-00667-9

01-06, Review

Abstract & Authors:展开

Abstract:收起
Symbiotic microorganisms inhabiting the gastrointestinal tract promote health by decreasing susceptibility to infection and enhancing resistance to a range of diseases. In this Review, we discuss our increasing understanding of the impact of the microbiome on the mammalian host and recent efforts to culture and characterize intestinal symbiotic microorganisms that produce or modify metabolites that impact disease pathology. Manipulation of the intestinal microbiome has great potential to reduce the incidence and/or severity of a wide range of human conditions and diseases, and the biomedical research community now faces the challenge of translating our understanding of the microbiome into beneficial medical therapies. Our increasing understanding of symbiotic microbial species and the application of ecological principles and machine learning are providing exciting opportunities for microbiome-based therapeutics to progress from faecal microbiota transplantation to the administration of precisely defined and clinically validated symbiotic microbial consortia that optimize disease resistance.

First Authors:
Matthew T Sorbara

Correspondence Authors:
Eric G Pamer

All Authors:
Matthew T Sorbara,Eric G Pamer

评论